New Technologies to Diagnose and Treat a Multidrug-Resistant Candida auris: A Patent Review

Rossato, Luana; Simionatto, Simone; Serafini, Mairim Russo; Alves, Izabel Almeida

doi:10.1007/s11046-022-00669-y

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serological marker ß-D glucan with the sensitivity of 92% is being used for the exclusion of IC [ 81 ]. The newer targets are being investigated [ 82 ]. The first-line of therapy for most Candida agents (except ENSY) is echinocandin, which can be stepped-down to fluconazole for C. albicans , C. parapsilosis , and C. tropicalis , while others ( C. krusei , C. glabrata , C. auris ) may respond to amphotericin B [ 83 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Candidiasis and Other Emerging Yeasts

Sharma

Chakrabarti²

2023

Curr Fungal Infect Rep

View full text Add to dashboard Cite

Purpose of Review The review presents a comprehensive and updated information on the contemporary status of invasive candidiasis (IC), other emerging yeast infections, and the challenges they present in terms of at-risk population, specific virulence attributes, and antifungal susceptibility profile. Recent Findings With the advancement in medical field, there has been parallel expansion of vulnerable populations over the past two decades. This had led to the emergence of a variety of rare yeasts in healthcare settings, both Candida and non-Candida yeast causing sporadic cases and outbreaks. The advancements in diagnostic modalities have enabled accurate identification of rare Candida species and non-Candida yeast (NCY) of clinical importance. Their distribution and susceptibility profile vary across different geographical regions, thus necessitating surveillance of local epidemiology of these infections to improve patient outcomes. Summary The challenges in management of IC have been complicated with emergence of newer species and resistance traits. C. tropicalis has already overtaken C. albicans in many Asian ICUs, while C. auris is rising rapidly worldwide. Recent genomic research has reclassified several yeasts into newer genera, and an updated version of MALDI-TOF MS or ITS sequencing is necessary for accurate identification. Having a knowledge of the differences in predisposing factors, epidemiology and susceptibility profile of already established pathogenic yeasts, as well as new emerging yeasts, are imperative for better patient management.

show abstract

Section: Introductionmentioning

confidence: 99%

“…including fluconazole/echinocandin resistant isolates [ 86 ]. With at least 16 new patents filed on diagnostic and therapeutic modalities for C. auris alone [ 82 ], contemporary and future research holds much promise for tackling the menace of candidiasis and other ever emerging yeasts.…”

Section: Introductionmentioning

confidence: 99%

Candidiasis and Other Emerging Yeasts

Sharma

Chakrabarti²

2023

Curr Fungal Infect Rep

View full text Add to dashboard Cite

show abstract

Characterization of susceptibility patterns and adaptability of the newly emerged Candida auris

Semenya,

Aladejana,

Ndlovu

2024

Int Microbiol

View full text Add to dashboard Cite

The emergence of Candida auris has caused a major concern in the public health worldwide. This novel fungus is characterized by its multidrug resistance profile, ability to thrive in harsh and stressful conditions, as well as high temperatures and salt concentrations, persistence on hospital surfaces, causing nosocomial infections and outbreaks, and unique fitness properties. Here, we study the antifungal susceptibility patterns, thermotolerance, and halotolerance of 15 putative C. auris clinical isolates from Inkosi Albert Academic Hospital, Durban, South Africa. Five of the C. auris isolates showed resistance to all three antifungals (fluconazole, amphotericin B, and micafungin) and were selected for characterization of their adaptability mechanisms. Four of the tested multidrug-resistant C. auris isolates (C. auris strain F25, C. auris strain F276, C. auris F283, and C. auris M153) showed good growth when exposed to high temperature (42 °C) and salinity (10% NaCl) conditions whereas one isolate (C. auris F65) showed moderate growth under these conditions. Candida parapsilosis showed poor growth whereas C. albicans no growth under these conditions. The five C. auris strains were positive for all the adaptive features.

show abstract

Current global status of Candida auris an emerging multidrug-resistant fungal pathogen: bibliometric analysis and network visualization

Ettadili,

Vural

2024

Braz J Microbiol

View full text Add to dashboard Cite

New Technologies to Diagnose and Treat a Multidrug-Resistant Candida auris: A Patent Review

Cited by 3 publications

References 32 publications

Candidiasis and Other Emerging Yeasts

Candidiasis and Other Emerging Yeasts

Characterization of susceptibility patterns and adaptability of the newly emerged Candida auris

Current global status of Candida auris an emerging multidrug-resistant fungal pathogen: bibliometric analysis and network visualization

Contact Info

Product

Resources

About